US agency questions AstraZeneca's Covid vaccine trial data

Drug firm may have provided incomplete view of efficacy data from US trial, says safety monitorCoronavirus – latest updatesSee all our coronavirus coverageThe Oxford/AstraZeneca vaccine against Covid has been dealt yet another blow within hours of the pharmaceutical company posting excellent results from its long-awaited big trial in the US.Questions have been raised in the US by the independent Data and Safety Monitoring Board (DSMB), which has suggested that AstraZeneca may have provided “outdated information” in its statement on Monday, which gave “an incomplete view” of the results.Continue reading...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: AstraZeneca Business Medical research Pharmaceuticals industry US news Infectious diseases Coronavirus Science World news Microbiology Source Type: news